Ranibizumab-aflibercept-ranibizumab treatment group (N = 10) | Wilcoxon p value | Friedman’s p value | Ranibizumab/bevacizumab-aflibercept-ranibizumab/bevacizumab treatment group (N = 9) | Wilcoxon p value | Friedman’s p value | |
---|---|---|---|---|---|---|
Median (interquartile range) | Median (interquartile range) | |||||
Central macular thickness (CMT), μm | 0.002 | 0.001 | ||||
OCT 1 | 335.5 (308.25–381.75) | 283 (252.5–382.5) | ||||
OCT 2 | 302.5 (222–360.75) | 0.030a | 285 (220.5–442.5) | 0.38a | ||
OCT 3 | 375 (292.75–435.25) | 0.016b | 295 (216.5–392.5) | 0.22b | ||
OCT 4 | 314 (232.5–399.75) | 0.021c | 248 (212.5–333.5) | 0.037c | ||
Total Fluid Volumed, mm3 | 0.007 | 0.003 | ||||
OCT 1 | 3.50 (2.47–5.52) | 1.68 (0.71–5.28) | ||||
OCT 2 | 3.55 (1.49–4.73) | 0.121a | 1.36 (0.58–4.20) | 0.221a | ||
OCT 3 | 4.28 (2.94–6.27) | 0.018b | 0.96 (0.76–3.85) | 0.297b | ||
OCT 4 | 2.87 (2.31–4.31) | 0.024c | 0.77 (0.47–2.72) | 0.087c | ||
Subretinal fluid (SRF), mm3 | 0.007 | 0.003 | ||||
OCT 1 | 0.11 (0.013–1.12) | 0.16 (0.003–0.82) | ||||
OCT 2 | 0.15 (0–0.76) | 0.091a | 0.11 (0.006–0.59) | 0.077a | ||
OCT 3 | 0.68 (0.01–1.68) | 0.178b | 0.33 (0.04–1.15) | 0.077b | ||
OCT 4 | 0.06 (0–0.40) | 0.004c | 0.09 (0.008–0.31) | 0.038c | ||
Intraretinal fluid (IRF), mm3 | 0.003 | 0.010 | ||||
OCT 1 | 0.04 (0–1.74) | 0 (0–0.73) | ||||
OCT 2 | 0.008 (0–0.07) | 0.032a | 0.0002 (0–0.49) | 0.426a | ||
OCT 3 | 0.22 (0.0006–0.96) | 0.012b | 0 (0–0.59) | 0.335b | ||
OCT 4 | 0.0009 (0–0.99) | 0.206c | 0 (0–0.44) | 0.377c | ||
Pigment Epithelial Detachment (PED), mm3 | 0.0003 | 0.003 | ||||
OCT 1 | 2.39 (1.77–3.23) | 0.67 (0.18–3.85) | ||||
OCT 2 | 2.36 (1.35–4.38) | 0.222a | 0.83 (0.20–3.40) | 0.430a | ||
OCT 3 | 2.49 (1.90–4.13) | 0.070b | 0.86 (0.18–2.63) | 0.107b | ||
OCT 4 | 2.39 (2.05–3.23) | 0.480c | 0.50 (0.16–2.03) | 0.187c |